Inhibikase Therapeutics Inc. (NASDAQ: IKT)
$1.51
-0.0300 ( -1.95% ) 27.7K
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
Market Data
Open
$1.51
Previous close
$1.54
Volume
27.7K
Market cap
$10.82M
Day range
$1.41 - $1.55
52 week range
$0.79 - $3.82
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Apr 03, 2024 |
4 | Insider transactions | 1 | Apr 02, 2024 |
8-k/a | 8K-related | 14 | Apr 02, 2024 |
3 | Insider transactions | 1 | Apr 02, 2024 |
10-k | Annual reports | 82 | Mar 27, 2024 |
8-k | 8K-related | 16 | Feb 07, 2024 |
8-k | 8K-related | 18 | Feb 01, 2024 |
8-k | 8K-related | 14 | Jan 16, 2024 |
10-q | Quarterly Reports | 64 | Nov 14, 2023 |
10-k/a | Quarterly Reports | 17 | Oct 16, 2023 |